EGFR and non-small cell lung carcinoma: To determine whether the combination of APG-2449, EGFR TKIs, and MEK TKIs can overcome acquired resistance to osimertinib in EGFR-mutated NSCLC, we analyzed the antiproliferative activity of APG-2449, alone or in tandem with other agents, in PC-9/OR cells with acquired osimertinib resistance (Fig. 5F).